News
Media
Conferences
Publications
CME/CE
Resources
Subscribe
About
Partnerships

|Articles|November 1, 2002

Is the cesarean rate too high? Yes.

Yes. It could be lower but it is difficult to know whether it really should be lower.

Newsletter

Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.

Related Content

Telehealth expands maternal-fetal medicine access, with Jeffrey Chapa, MD

Telehealth expands maternal-fetal medicine access, with Jeffrey Chapa, MD

ByJeffery Chapa, MD

July 24th 2026

CMS proposed G-codes for obstetric billing draw concern from ACOG amid coding transition

Updated: CMS proposed G-codes for obstetric billing draw concern from ACOG amid coding transition

ByJoshua Fitch, Senior Editor

Published: July 24th 2026 | Updated: July 24th 2026

FDA grants 510(k) clearance to Roche's cobas BV/CV assay

FDA grants 510(k) clearance to Roche's cobas BV/CV assay

ByJoshua Fitch, Senior Editor

July 24th 2026

Closing the STI screening and follow-up gap in pregnancy, with Damian Alagia, III, MD

Closing the STI screening and follow-up gap in pregnancy, with Damian Alagia, III, MD

ByJoshua Fitch, Senior Editor ,Damian Alagia, III, MD, MS, MBA, FACS,

July 23rd 2026

HIV screening, PrEP counseling get stronger ACOG recommendation

HIV screening, PrEP counseling get stronger ACOG recommendation

ByContemporary OB/GYN Staff

July 23rd 2026

Latest CME

SimulatEd™: A Roadmap to Personalized Care Plans and Shared Decision-Making in Low-Grade Serous Ovarian Cancer

Case-based Simulation

SimulatEd™: A Roadmap to Personalized Care Plans and Shared Decision-Making in Low-Grade Serous Ovarian Cancer

Rachel N. Grisham, MD

Trending on Contemporary OB/GYN

HIV screening, PrEP counseling get stronger ACOG recommendation

Telehealth expands maternal-fetal medicine access, with Jeffrey Chapa, MD

Updated: CMS proposed G-codes for obstetric billing draw concern from ACOG amid coding transition

Biomarker testing for preeclampsia with Lisa A. Bukovac, DO, FACOG

FDA grants 510(k) clearance to Roche's cobas BV/CV assay